IP Verse

Nad-Augmentation Therapy For Parkinson'S Disease - EP4284387

The patent EP4284387 was granted to Vestlandets Innovasjonsselskap VIS on Jul 31, 2024. The application was originally filed on Jun 24, 2022 under application number EP22740800A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP4284387

VESTLANDETS INNOVASJONSSELSKAP VIS
Application Number
EP22740800A
Filing Date
Jun 24, 2022
Status
Granted And Under Opposition
Jun 27, 2024
Grant Date
Jul 31, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

IMMUNOPHARMAApr 29, 2025WEICKMANN & WEICKMANN PARTMBBADMISSIBLE

Patent Citations (6) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTWO2018039207
INTERNATIONAL-SEARCH-REPORTWO2020257283
INTERNATIONAL-SEARCH-REPORTWO2022028678
OPPOSITIONUS4970200
OPPOSITIONWO2013045538
OPPOSITIONWO2018039207

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "70. Parkinsonmittel und andere Mittel gegen extrapyramidale Störungen", Anonymous, Rote Liste® Service GmbH, Rote Liste 2016, Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte), 56. Ausgabe, Frankfurt/Main, Rote Liste® Service GmbH, (20160101), pages 1057 - 1077, ISBN 978-3-946057-00-0, XP009561652-
OPPOSITION- Anonymous, "Levodopa", Gelbe Liste, (20200427), Gelbe Liste, URL: https://www.gelbe-liste.de/wirkstoffe/Levodopa_1974#, XP093277018-
OPPOSITION- D16a - Printout from PubMed website regarding Pirvu et al. (E16)-
OPPOSITION- Haukeland University Hospital, "A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease (NOPARK) - NCT03568968", Clinical Trials, clinicaltrials.gov, (20200605), Clinical Trials, URL: https://clinicaltrials.gov/study/NCT03568968?a=4&tab=history#version-content-panel, XP093277011-
OPPOSITION- Haukeland University Hospital, "NAD-supplementation in Drug naïve Parkinson's Disease (NAD-PARK) - NCT03816020", Clinical Trials, clinicaltrials.gov, (20200210), Clinical Trials, URL: https://clinicaltrials.gov/study/NCT03816020?term=NCT03816020&rank=1&a=4&tab=history, XP093277026-
OPPOSITION- Haukeland University Hospital, "NAD-supplementation in Drug naïve Parkinson's Disease (NAD-PARK) - NCT03816020", Clinical Trials, clinicaltrials.gov, (20200210), Clinical Trials, URL: https://clinicaltrials.gov/study/NCT03816020?term=NCT03816020&rank=1&a=4, XP093277027-
OPPOSITION- Huang Juebin, "Dementia with Lewy Bodies and Parkinson Disease Dementia", MSD Manual - Professional Version, (20250201), XP093276998-
OPPOSITION- "SINEMET (carbidopa and levodopa) Tablets - product information leaflet", (20210601), pages 1 - 10, URL: https://www.organon.com/product/usa/pi_circulars/s/sinemet/sinemet_pi.pdf, XP093276554-
OPPOSITION- Schöndorf et al., "The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC and Fly Models of Parkinson's Disease", Cell Reports, (2018), vol. 23, doi:10.1016/j.celrep.2018.05.009, XP055772467
OPPOSITION- Dietrich Conze, Charles Brenner, Claire L. Kruger, "Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults", Scientific Reports, (20191201), vol. 9, no. 1, doi:10.1038/s41598-019-46120-z, XP055766111
OPPOSITION- Bogan and Brenner, "Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition", Annu. Rev. Nutr., (2008), vol. 28, doi:10.1146/annurev.nutr.28.061807.155443, XP055461560
OPPOSITION- Zhang Zhenxian, Hamada Hiroki, Gerk Phillip M., "Selectivity of Dietary Phenolics for Inhibition of Human Monoamine Oxidases A and B", BioMed Research International, Hindawi Publishing Corporation, (20190123), vol. 2019, doi:10.1155/2019/8361858, ISSN 2314-6133, pages 1 - 12, XP093277014
OPPOSITION- Mills Edward; Prousky Jonathan; Raskin Gannady; Gagnier Joel; Rachlis Beth; Montori Victor M; Juurlink David, "The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]", BMC CLINICAL PHARMACOLOGY, BIOMED CENTRAL, LONDON, GB, GB , (20031113), vol. 3, no. 1, doi:10.1186/1472-6904-3-4, ISSN 1472-6904, page 4, XP021006479
OPPOSITION- Chong Raymond, Wakade Chandramohan, Seamon Marissa, Giri Banabihari, Morgan John, Purohit Sharad, "Niacin Enhancement for Parkinson’s Disease: An Effectiveness Trial", Frontiers in Aging Neuroscience, Frontiers Research Foundation, CH, CH , vol. 13, doi:10.3389/fnagi.2021.667032, ISSN 1663-4365, XP093277013
OPPOSITION- Pîrvu Andreea, Andrei Ana, Stănciulescu Elena, Baniță Ileana, Pisoschi Cătălina, Jurja Sanda, Ciuluvica Radu, "NAD + metabolism and retinal degeneration (Review)", EXPERIMENTAL AND THERAPEUTIC MEDICINE, Spandidos Publications, GR, GR , vol. 22, no. 1, doi:10.3892/etm.2021.10102, ISSN 1792-0981, XP093277015

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents